Cleave Biosciences Gets $37M
Burlingame-based Cleave Biosciences, a developer of protein-based technology for treating cancer, has raised $37M in a Series B funding round. The funding came from Celgene, Nextech Invest Ltd. and Arcus Ventures, plus 5AM Ventures, Clarus Ventures, New Enterprise Associates (NEA), Orbimed Advisors, U.S. Venture Partners, Astellas Venture Management and Osage University Partners. Alfred Scheidegger of Nextech Invest, and Carol Gallaghers of NEA have boh joined the companys board of directors. Laura Shawver, Ph.D. is CEO of Cleave Biosciences.
posted on Monday, August 8, 2016 (Link to more information)
Related companies:
Cleave Biosciences
Related stories:
> Cleave Biosciences Gets $42M For Cancer Therapies
> Cleave Biosciences Adds $10M In Series A
> 3-V Biosciences Finds $20M In Funding
> Pacific Biosciences Raises $50M
> Imago Biosciences Sees $26.5M
silicontap.com Home